ClinicalTrials.gg
CompletedNCT03591406Updated Jun 10, 2021Results posted

To Assess the Impact of Ferric Carboxymaltose Compared With Iron Sucrose in Chinese Subjects on Correcting Iron Deficiency Anaemia

A Phase 3 interventional study of Ferric carboxymaltose and Iron sucrose in Iron Deficiency Anemia, sponsored by Vifor (International) Inc.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-10.

Sponsored by Vifor (International) Inc. (part of CSL Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Jul 2017, registered Jun 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
371
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency — 7 open to participants now, 7 under way, none of them phase 3. ferric carboxymaltose · Anemia, Iron-Deficiency.

Enrollment
12th of 57
371 · median 100
Started
2017
with 8 others
Phase 3
16 of 57
none open now
Registered
30th of 57
by date

Among the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, this one is the 12th largest by enrollment, is one of 9 that started in 2017, is one of 16 in phase 3, and was the 30th registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

7 of the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

The primary objective is to demonstrate the efficacy of ferric carboxymaltose (FCM) given in a simple dosing regimen in correcting iron deficiency anaemia (IDA), by demonstrating non-inferiority to treatment with the currently approved intravenous (IV) iron therapy of iron sucrose (IS, Venofer™) in the Chinese population. The secondary objectives are to assess the safety of FCM compared to IS in the Chinese population and to evaluate the effect of FCM compared to IS on relevant laboratory parameters (haematology, chemistry, iron parameters) in the Chinese population.

Read the detailed description

This is an open-label, randomised controlled study to assess the impact of FCM in correcting iron deficiency anaemia compared with Venofer™ (IS).

All subjects, after providing written informed consent and meeting the eligibility assessments, will receive a first dose of IV iron as either FCM or IS. A total of approximately 368 subjects (184 per group) will be enrolled. All subjects will have iron deficiency anaemia as measured by haemoglobin (Hb), serum ferritin and transferrin saturation (TSAT) at screening.

Ferric carboxymaltose will be administered as either a diluted infusion or undiluted injection (at Investigator discretion) and IS will be administered as a slow intravenous injection at a rate of 1 ml undiluted solution per minute (with each single injection of 200 mg iron) or by drip infusion. Note, for subjects randomised to receive IS dosing visits are required three times a week to achieve total iron repletion dosing as calculated using the Ganzoni formula.

For subjects randomised to FCM, the total iron requirements will be calculated at screening based on the screening Hb and subject weight. Dosing will be at baseline and, if required, at day 8 and day 15. All subjects will attend study visits at screening, baseline and thereafter at Weeks 2, 4 and 6. All subjects will attend an end of study visit (at Week 8 - or earlier if discontinued prematurely).

03

Conditions studied

  • Iron Deficiency Anemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age
  • \<11 g/dL (females) or Hb \<12 g/dL (males) at the screening visit
  • Serum ferritin \<100 ng/mL for subjects with underlying inflammatory disease (e.g., inflammatory bowel disease (IBD), chronic kidney disease (CKD) or chronic heart failure (CHF), as determined by high sensitive C-reactive protein [hsCRP] levels above the normal range) otherwise ≤14 ng/mL in subjects with no apparent underlying inflammatory disease (as determined by hsCRP levels within normal range) at the screening visit
  • Transferrin Saturation (TSAT) \<16% (any subject) at the screening visit
  • Microcytic, hypochromic anaemia defined as: a) Mean corpuscular Hb concentration (MCHC) \<32%; b) Mean corpuscular volume (MCV) \< 80 fL; c)Mean corpuscular Hb (MCH) \<27 pg
  • Subjects with the ability to understand the requirements of the study and abide by the study restrictions, and who agree to return for the required assessments
  • Before any study-specific procedure is conducted, the appropriate written must be obtained

Exclusion criteria

Exclusion Criteria:

  • Subject has known to any of the products to be administered during dosing
  • Any history of iron storage diseases such as haemochromatosis
  • Any history or clinical findings of iron utilisation disorders such as sideroachrestic anaemia
  • Known haemoglobinopathy (e.g. thalassaemia)
  • Any history or clinical findings of anaemia associated with: a) Haematuria b) Vitamin B12 or folic acid deficiency that requires treatment (subjects can be included after deficiency is corrected)
  • Any allergic predispositions, i.e. any history of asthma or atopic allergy. This includes drug allergies.
  • Planned surgery with anticipated blood loss (defined as drop >2 g/dL) in the 3 months post randomisation
  • Subject has known (with or without current treatment), except basal cell or squamous cell carcinoma of the skin or cervical intra-epithelial neoplasia
  • Haemodialysis (current or planned within the next 3 months)
  • History of IV iron therapy, erythropoiesis stimulating agent (ESA) therapy and/or blood transfusion in previous 4 weeks prior to screening, and oral iron or oral iron-containing products including Chinese herbal medicines (>75mg iron/day) in the 7 days prior to screening
  • Body weight \<35 kg
  • Chronic liver disease and/or screening (ALT) or aspartate transaminase (AST) above 3 times the
  • Known infection, acquired immunodeficiency syndrome, tuberculosis
  • Known active or C or other active infection (acute or chronic)
  • Subject currently is enrolled in or has not yet completed at least 30 days since ending other device or drug study(ies), or subject is receiving other investigational agent(s)
  • Subject is pregnant or is breast feeding
  • Female subject of not using adequate methods during the study and for up to 1 month after the last dose of the study medication. Adequate contraceptive methods are defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra-uterine devices, sexual abstinence or vasectomised partner. Non-childbearing potential includes being surgically sterilised at least 6 months prior to the study or , defined as amenorrhoea for at least 12 months
  • Male subjects planning to father a child within 7 days from the last study drug administration.
  • Subject has any kind of disorder that compromises the ability of the subject to give written and/or to comply with study procedures and/or other reason(s) that render subject not appropriate for study participation in the opinion of the treating physician
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
371 participants (actual)

Study arms

  • Experimental
    Ferric carboxymaltose (FCM)

    Subjects treated with FCM given by IV injection or drip infusion

    Drug: Ferric carboxymaltose

  • Active comparator
    Iron sucrose (IS)

    Subjects treated with IS given by IV injection or drip infusion

    Drug: Iron sucrose

Interventions

  • Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection Strength: 10 mL vials containing 500 mg iron per vial Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening) Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline) Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.

    Also known as: FCM

  • Dosage Form: Sterile solution for injection containing 2% w/v iron Strength: 5 mL ampoules containing 100 mg iron per ampoule Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit \[mg\] = BW \[kg\] x (target Hb- actual Hb) \[g/dL\] x 2.4 + 500 mg, up to 11 IS injections will be given Route of administration: IV injection or drip infusion Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.

    Also known as: IS, Venofer™

06

What researchers measure

Primary outcomes

  1. Participants Achieving an Increase in Hb of at Least 2 g/dL at Any Time up to Week 8

    Haemoglobin (Hb)

    Time frame: From baseline at any time up to Week 8

Secondary outcomes

  1. Participants Achieving an Increase in Hb of at Least 2 g/dL From Baseline to Weeks 2, 4, 6 and 8

    Haemoglobin (Hb)

    Time frame: From Baseline to weeks 2, 4, 6 and 8

  2. Change in Hb From Baseline to Weeks 2, 4, 6, and 8

    Haemoglobin (Hb)

    Time frame: From Baseline to weeks 2, 4, 6 and 8

  3. Participants With Iron Deficiency Correction Over Time by Treatment

    Iron deficiency correction: TSAT \>= 16% and serum ferritin \>=100ng/mL (for subjects with underlying inflammatory disease) or \>14ng/mL (for subjects with no apparent underlying inflammatory disease).

    Time frame: From Baseline to Weeks 2, 4, 6 and 8

  4. Change in TSAT From Baseline to Weeks 2, 4, 6 and 8

    Transferrin saturation (TSAT)

    Time frame: From Baseline to weeks 2, 4, 6 and 8

  5. Change in Serum Ferritin From Baseline to Weeks 2, 4, 6 and 8

    Time frame: From Baseline to Weeks 2, 4, 6 and 8

  6. Change in Serum Iron From Baseline to Weeks 2, 4, 6 and 8

    Time frame: From Baseline to weeks 2, 4, 6 and 8

  7. Participants With Any Treatment Emergent Adverse Event (TEAE)

    Please note that in this section we are presenting just the overview of the adverse events experienced by the trial participant, in particular, the number of participants with at least one TEAE until end of the trial. Please refer to the detailed tables included on the Adverse Event Module for specifics

    Time frame: From Baseline to the End of the study (week 8)

  8. Blood Pressure at Baseline and Weeks 2, 4, 6 and 8

    Diastolic Blood pressure

    Time frame: Baseline and weeks 2, 4, 6 and 8

  9. Body Weight at Baseline and Week 8

    Time frame: Baseline and week 8

  10. Heart Rate at Baseline and Weeks 2, 4, 6 and 8

    Time frame: Baseline and weeks 2, 4, 6 and 8

  11. Body Temperature at Baseline and Weeks 2, 4, 6 and 8

    Time frame: Baseline and weeks 2, 4, 6 and 8

07

Results

Posted May 18, 2020

Participant flow

Participant flow — Overall Study
MilestoneFerric Carboxymaltose (FCM)Iron Sucrose (IS)
Started188183
Completed181174
Not completed79
Withdrew: Adverse event53
Withdrew: Protocol violation21
Withdrew: Withdrawal by subject05

Outcome measures

PrimaryParticipants Achieving an Increase in Hb of at Least 2 g/dL at Any Time up to Week 8

Haemoglobin (Hb)

Time frame:
From baseline at any time up to Week 8
Reported as:
Count of participants · Participants
Participants Achieving an Increase in Hb of at Least 2 g/dL at Any Time up to Week 8
ParticipantsFerric Carboxymaltose (FCM)Iron Sucrose (IS)
Participants Achieving an Increase in Hb of at Least 2 g/dL at Any Time up to Week 8176175
Statistical analysis
  • Ferric Carboxymaltose (FCM) vs Iron Sucrose (IS) · Difference in proportions: 1.12 · 95% CI -2.15 to 4.712-sided 95% Confidence Interval (CI) was computed using the Wilson score method with continuity correction described by Newcombe.
SecondaryParticipants Achieving an Increase in Hb of at Least 2 g/dL From Baseline to Weeks 2, 4, 6 and 8

Haemoglobin (Hb)

Time frame:
From Baseline to weeks 2, 4, 6 and 8
Reported as:
Count of participants · Participants
Participants Achieving an Increase in Hb of at Least 2 g/dL From Baseline to Weeks 2, 4, 6 and 8
ParticipantsFerric Carboxymaltose (FCM)Iron Sucrose (IS)
Week 2150129
Week 4164167
Week 6169168
Week 8173171
SecondaryChange in Hb From Baseline to Weeks 2, 4, 6, and 8

Haemoglobin (Hb)

Time frame:
From Baseline to weeks 2, 4, 6 and 8
Reported as:
Mean · g/dL
Change in Hb From Baseline to Weeks 2, 4, 6, and 8
g/dLFerric Carboxymaltose (FCM)Iron Sucrose (IS)
Week 23.01 ± 1.1352.53 ± 1.016
Week 44.46 ± 1.5024.08 ± 1.217
Week 64.96 ± 1.4354.61 ± 1.422
Week 85.09 ± 1.5044.87 ± 1.525
SecondaryParticipants With Iron Deficiency Correction Over Time by Treatment

Iron deficiency correction: TSAT \>= 16% and serum ferritin \>=100ng/mL (for subjects with underlying inflammatory disease) or \>14ng/mL (for subjects with no apparent underlying inflammatory disease).

Time frame:
From Baseline to Weeks 2, 4, 6 and 8
Reported as:
Count of participants · Participants
Participants With Iron Deficiency Correction Over Time by Treatment
ParticipantsFerric Carboxymaltose (FCM)Iron Sucrose (IS)
Week 2173135
Week 4165168
Week 6161163
Week 8162154
SecondaryChange in TSAT From Baseline to Weeks 2, 4, 6 and 8

Transferrin saturation (TSAT)

Time frame:
From Baseline to weeks 2, 4, 6 and 8
Reported as:
Mean · Percentage of TSAT
Change in TSAT From Baseline to Weeks 2, 4, 6 and 8
Percentage of TSATFerric Carboxymaltose (FCM)Iron Sucrose (IS)
Week 230.16 ± 11.74125.03 ± 19.474
Week 428.00 ± 8.52825.30 ± 8.453
Week 625.50 ± 9.09723.33 ± 7.868
Week 825.32 ± 10.79320.82 ± 7.618
SecondaryChange in Serum Ferritin From Baseline to Weeks 2, 4, 6 and 8
Time frame:
From Baseline to Weeks 2, 4, 6 and 8
Reported as:
Mean · ng/ml
Change in Serum Ferritin From Baseline to Weeks 2, 4, 6 and 8
ng/mlFerric Carboxymaltose (FCM)Iron Sucrose (IS)
Week 2759.72 ± 331.118385.51 ± 145.647
Week 4379.31 ± 195.415280.58 ± 148.913
Week 6255.71 ± 152.582184.93 ± 100.677
Week 8202.09 ± 148.382145.56 ± 89.890
SecondaryChange in Serum Iron From Baseline to Weeks 2, 4, 6 and 8
Time frame:
From Baseline to weeks 2, 4, 6 and 8
Reported as:
Mean · umol/L
Change in Serum Iron From Baseline to Weeks 2, 4, 6 and 8
umol/LFerric Carboxymaltose (FCM)Iron Sucrose (IS)
Week 215.53 ± 7.07516.23 ± 14.512
Week 412.31 ± 4.20912.39 ± 4.724
Week 610.77 ± 4.31811.27 ± 4.160
Week 810.77 ± 4.87110.09 ± 4.152
SecondaryParticipants With Any Treatment Emergent Adverse Event (TEAE)

Please note that in this section we are presenting just the overview of the adverse events experienced by the trial participant, in particular, the number of participants with at least one TEAE until end of the trial. Please refer to the detailed tables included on the Adverse Event Module for specifics

Time frame:
From Baseline to the End of the study (week 8)
Reported as:
Count of participants · Participants
Participants With Any Treatment Emergent Adverse Event (TEAE)
ParticipantsFerric Carboxymaltose (FCM)Iron Sucrose (IS)
Participants With Any Treatment Emergent Adverse Event (TEAE)124101
SecondaryBlood Pressure at Baseline and Weeks 2, 4, 6 and 8

Diastolic Blood pressure

Time frame:
Baseline and weeks 2, 4, 6 and 8
Reported as:
Mean · mmHg
Blood Pressure at Baseline and Weeks 2, 4, 6 and 8
mmHgFerric Carboxymaltose (FCM)Iron Sucrose (IS)
Baseline69.8 ± 7.9171.9 ± 8.85
Week 271.0 ± 8.3372.6 ± 8.79
Week 472.1 ± 7.6073.8 ± 9.57
Week 671.6 ± 8.1874.3 ± 9.24
Week 872.4 ± 8.0974.1 ± 9.77
SecondaryBody Weight at Baseline and Week 8
Time frame:
Baseline and week 8
Reported as:
Mean · kg
Body Weight at Baseline and Week 8
kgFerric Carboxymaltose (FCM)Iron Sucrose (IS)
Baseline59.76 ± 9.38460.40 ± 9.354
Week 859.73 ± 9.31660.64 ± 9.372
SecondaryHeart Rate at Baseline and Weeks 2, 4, 6 and 8
Time frame:
Baseline and weeks 2, 4, 6 and 8
Reported as:
Mean · beats/min
Heart Rate at Baseline and Weeks 2, 4, 6 and 8
beats/minFerric Carboxymaltose (FCM)Iron Sucrose (IS)
Baseline81.4 ± 8.8582.2 ± 9.94
Week 276.3 ± 9.8076.5 ± 8.83
Week 475.5 ± 10.7176.6 ± 10.79
Week 676.0 ± 8.9877.2 ± 10.04
Week 875.8 ± 10.3377.5 ± 10.94
SecondaryBody Temperature at Baseline and Weeks 2, 4, 6 and 8
Time frame:
Baseline and weeks 2, 4, 6 and 8
Reported as:
Mean · ºC
Body Temperature at Baseline and Weeks 2, 4, 6 and 8
ºCFerric Carboxymaltose (FCM)Iron Sucrose (IS)
Baseline36.94 ± 0.29236.45 ± 0.325
Week 236.48 ± 0.26936.44 ± 0.288
Week 436.49 ± 0.26936.40 ± 0.268
Week 636.47 ± 0.25936.41 ± 0.260
Week 836.48 ± 0.26936.46 ± 0.257

Adverse events

Collected over From Baseline until the End of the Study (8 weeks). Non-serious events are listed at a 2.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ferric Carboxymaltose (FCM)0/187 (0%)10/187 (5.3%)124/187 (66.3%)
Iron Sucrose (IS)0/180 (0%)7/180 (3.9%)92/180 (51.1%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventFerric Carboxymaltose (FCM)Iron Sucrose (IS)
Crohn's diseaseGastrointestinal disorders1/1872/180
MenorrhagiaReproductive system and breast disorders0/1872/180
Abdominal adhesionsGastrointestinal disorders0/1871/180
AdenomyosisReproductive system and breast disorders0/1871/180
Pelvic adhesionsReproductive system and breast disorders0/1871/180
Anaphylactic shockImmune system disorders0/1871/180
Urinary tract infectionInfections and infestations0/1871/180
PyrexiaGeneral disorders0/1871/180
Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1870/180
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1870/180
Most frequent other events
Showing 10 of 20
Most frequent other events
EventFerric Carboxymaltose (FCM)Iron Sucrose (IS)
HypophosphataemiaMetabolism and nutrition disorders19/1875/180
Upper respiratory tract infectionInfections and infestations15/18713/180
Urine phosphorus decreasedInvestigations14/18714/180
Blood phosphorus decreasedInvestigations13/1871/180
Hepatic function abnormalHepatobiliary disorders13/1879/180
PyrexiaGeneral disorders12/1873/180
Alanine aminotransferase increasedInvestigations11/1875/180
White blood cells urine positiveInvestigations7/1878/180
Urinary tract infectionInfections and infestations6/1877/180
Aspartate aminotransferase increasedInvestigations7/1874/180

Baseline characteristics

Demography and baseline characteristics for the Safety Set (SS) are provided. The SS was defined as all randomised subjects who received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(years)Ferric Carboxymaltose (FCM)Iron Sucrose (IS)Total
Mean39.9 ± 9.8538.9 ± 8.7039.4 ± 9.31
Sex: Female, Male
Sex: Female, Male(Participants)Ferric Carboxymaltose (FCM)Iron Sucrose (IS)Total
Female173169342
Male141125
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ferric Carboxymaltose (FCM)Iron Sucrose (IS)Total
American Indian or Alaska Native000
Asian187180367
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Ferric Carboxymaltose (FCM)Iron Sucrose (IS)Total
China187180367
Haemoglobin
Haemoglobin(g/dl)Ferric Carboxymaltose (FCM)Iron Sucrose (IS)Total
Mean7.74 ± 1.4918.06 ± 1.4537.90 ± 1.479
Serum ferritin
Serum ferritin(ng/ml)Ferric Carboxymaltose (FCM)Iron Sucrose (IS)Total
Mean4.47 ± 2.1454.93 ± 6.0954.70 ± 4.534
Transferrin saturation (TSAT)
Transferrin saturation (TSAT)(%)Ferric Carboxymaltose (FCM)Iron Sucrose (IS)Total
Mean4.82 ± 1.8984.92 ± 2.9124.87 ± 2.446
High-sensitivity C-reactive protein (hsCRP)
High-sensitivity C-reactive protein (hsCRP)(mg/l)Ferric Carboxymaltose (FCM)Iron Sucrose (IS)Total
Mean1.026 ± 2.14321.567 ± 5.98171.291 ± 4.4617
08

Study locations

1 site
  • The First Affiliated Hospital, Zhejiang University
    Hangzhou, Zhejiang 310003, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Feb 2019, 19 months.

Results were first posted in May 2020, 1 year 2 months after primary completion.

Of 49 phase 3 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2018
First posted
Jul 19, 2018
StartActual
Jul 3, 2017
Primary completionActual
Feb 25, 2019
CompletionActual
Feb 25, 2019
Results first posted
May 18, 2020
Last update
Jun 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03591406
Collaborators
Tigermed Consulting Co., Ltd
Responsible party
Sponsor
First posted
Jul 19, 2018
Start date
Jul 3, 2017
Primary completion
Feb 25, 2019
Completion
Feb 25, 2019
Results posted
May 18, 2020
Last update
Jun 10, 2021

Study contacts

Jie Jin
principal investigator · The First Affiliated Hospital, Zhejiang University
Zhihua Ran
principal investigator · Renji Hospital Shanghai Jiaotong Uniersity School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion